 | A major contributor to this article appears to have a close connection with its subject. (May 2024) |
 | |
| Company type | Public |
|---|---|
| Industry | Pharmaceuticals |
| Founded | April 7, 2014 |
| Founder | Vivek Ramaswamy |
| Headquarters | London, United Kingdom |
Key people | Matt Gline (CEO) |
| Revenue |  US$61 million (fiscal 2023) |
 US$−1.1 billion (fiscal 2023) | |
| Total assets | US$2.39 billion (fiscal 2023) |
| Total equity | US$1.61 billion (fiscal 2023) |
| Owner | Vivek Ramaswamy (10.5%) |
Number of employees | ≈ 904 (March 2023) |
| Website | roivant |
| Footnotes / references [1][2] | |
Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.
- ^ "FY2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commisssion. 28 June 2023. Archived from the original on 26 August 2023. Retrieved 26 August 2023.
- ^ "2023 Proxy Statement". Archived from the original on 2023-09-02. Retrieved 2023-09-02.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search